Literature DB >> 22129349

Clinical spectrum of atypical fibroxanthoma and undifferentiated pleomorphic sarcoma in solid organ transplant recipients: a collective experience.

Holly H McCoppin1, Daniel Christiansen, Thomas Stasko, Carl Washington, Juan Carlos Martinez, Marc D Brown, Fiona O Zwald.   

Abstract

BACKGROUND: Atypical fibroxanthoma (AFX) and undifferentiated pleomorphic sarcoma (UPS) are uncommon, spindle cell cutaneous malignancies. Solid organ transplant recipients (SOTRs) are immunosuppressed and therefore have a higher incidence of cutaneous malignancies.
OBJECTIVE: We describe the clinical spectrum of AFX and a more-aggressive, deeper variant, UPS, in SOTRs.
MATERIALS AND METHODS: A retrospective chart review of AFX and UPS in SOTRs was implemented. Cases from Vanderbilt University, Emory University, Mayo Clinic-Jacksonville, and University of Rochester were included. A literature search included previously published cases.
RESULTS: The average age of SOTRs at time of tumor presentation was younger than typically seen in immunocompetent patients for AFX. Rates of local recurrences and metastases were higher in the SOTRs than is noted in the immunocompetent literature. Rates of recurrence were higher in those treated with excision than in those treated with Mohs micrographic surgery (MMS).
CONCLUSION: AFX and UPS may have a greater risk for recurrence, metastases, and mortality in SOTRs, in whom early treatment with MMS may demonstrate certain advantages in terms of minimizing risk of recurrence and metastasis. UPS and recurrent tumors should be staged appropriately and may respond to adjuvant radiation therapy and reduction of immunosuppression. Immunohistochemical evaluation is recommended to exclude other spindle cell tumors.
© 2011 by the American Society for Dermatologic Surgery, Inc. Published by Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22129349     DOI: 10.1111/j.1524-4725.2011.02180.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  6 in total

1.  Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles.

Authors:  Klaus G Griewank; Thomas Wiesner; Rajmohan Murali; Carina Pischler; Hansgeorg Müller; Christian Koelsche; Inga Möller; Cindy Franklin; Ioana Cosgarea; Antje Sucker; Dirk Schadendorf; Jörg Schaller; Susanne Horn; Thomas Brenn; Thomas Mentzel
Journal:  Mod Pathol       Date:  2017-11-03       Impact factor: 7.842

Review 2.  Conception and Management of a Poorly Understood Spectrum of Dermatologic Neoplasms: Atypical Fibroxanthoma, Pleomorphic Dermal Sarcoma, and Undifferentiated Pleomorphic Sarcoma.

Authors:  Teo Soleymani; S Tyler Hollmig
Journal:  Curr Treat Options Oncol       Date:  2017-08

3.  Risk of Second Malignancies in Solid Organ Transplant Recipients Who Develop Keratinocyte Cancers.

Authors:  Rachel D Zamoiski; Elizabeth Yanik; Todd M Gibson; Elizabeth K Cahoon; Margaret M Madeleine; Charles F Lynch; Sally Gustafson; Marc T Goodman; Melissa Skeans; Ajay K Israni; Eric A Engels; Lindsay M Morton
Journal:  Cancer Res       Date:  2017-06-14       Impact factor: 13.312

4.  Revision of immunosuppression in a solid organ transplant recipient leads to complete remission of metastatic undifferentiated carcinoma.

Authors:  Abigail H Waldman; Jennifer M McNiff; AnnMarie Liapakis; William S Asch; Stephanie Smith-Marrone; Oscar R Colegio
Journal:  JAAD Case Rep       Date:  2015-11-24

5.  Pleomorphic Dermal Sarcoma of the Scalp.

Authors:  Nikolai Klebanov; Mai P Hoang; Bobby Y Reddy
Journal:  Cureus       Date:  2018-07-13

6.  Lethal Dermal Sarcoma in Immunosuppressed Patients.

Authors:  Marjan Azin; Amir H Ameri; Ruth K Foreman; Victor A Neel; Mayra E Lorenzo; Shadmehr Demehri
Journal:  Oncologist       Date:  2022-09-02       Impact factor: 5.837

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.